ADVENTRX Reports Thiovir Active Against Various Influenza A Viruses in Series of Independent Preclinical Tests
January 31 2006 - 11:30AM
PR Newswire (US)
SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX) announced today that a series of
independent preclinical tests confirmed inhibition of influenza A
virus by the Company's broad spectrum anti-viral drug, Thiovir(TM).
The Company is conducting preclinical research on influenza A,
which includes the H5N1 avian flu strain. The tests are being
conducted in collaboration with Virapur, LLC., a virology specialty
company in San Diego, and lead investigator Marylou Gibson, Ph.D.
The Company filed a provisional patent application with the US
Patent and Trademark Office on January 27, 2006 in connection with
these findings. Thiovir is a broad spectrum anti-viral agent and
non-nucleoside reverse transcriptase inhibitor (NNRTI) designed for
oral delivery and as a component of highly active antiretroviral
therapy (HAART) for HIV/AIDS. "Published data show that the avian
influenza polymerase subsequence, PB1, is highly conserved. Since
Thiovir's proposed mechanism of action is inhibition of the
polymerase PB1 subunit, we began to investigate the possible use of
Thiovir for avian flu," said Joan M. Robbins, Ph.D., ADVENTRX chief
scientific officer and executive vice president. "Additional
confirmatory tests for Thiovir in avian flu and other viruses are
planned. A preclinical package for Thiovir with extensive
pharmacology and toxicology studies is already in development for
our HIV program and we believe this would help expedite the
clinical development of Thiovir for other indications, such as in
the treatment of avian flu." About Thiovir Thiovir is a broad
spectrum anti-viral and a non-nucleoside reverse transcriptase
inhibitor (NNRTI) designed for oral delivery as a component of
HAART. Thiovir is a prodrug for foscarnet that delivers both the
active drug TPFA (thiophosphonoformate) and the active metabolite
PFA (foscarnet) in an oral formulation. Thiovir is intended to
deliver the benefits of the drug foscarnet, including broad
spectrum antiviral activity, with the added benefit of improved
bioavailability. ADVENTRX currently plans to file an
investigational new drug application with the US Food and Drug
Administration in the first half of 2006 for testing of Thiovir in
patients with HIV/AIDS. About ADVENTRX ADVENTRX Pharmaceuticals is
a biopharmaceutical research and development company focused on
introducing new technologies for anticancer and antiviral
treatments that surpass the performance and safety of existing
drugs, by addressing significant problems such as drug metabolism,
toxicity, bioavailability and resistance. More information can be
found on the Company's Web site at http://www.adventrx.com/.
Forward-Looking Statement This press release contains
forward-looking statements, within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995,
regarding ADVENTRX. Such statements are made based on management's
current expectations and beliefs. Actual results may vary from
those currently anticipated based upon a number of factors,
including uncertainties inherent in the drug development process,
the timing and success of clinical trials, the validity of research
results, and the receipt of necessary approvals from the FDA and
other regulatory agencies. For a discussion of such risks and
uncertainties, which could cause actual results to differ from
those contained in the forward-looking statements regarding
ADVENTRX, see the section titled "Risk Factors" in ADVENTRX's last
quarterly report on Form 10-Q, as well as other reports that
ADVENTRX files from time to time with the Securities and Exchange
Commission. All forward-looking statements regarding ADVENTRX are
qualified in their entirety by this cautionary statement. ADVENTRX
undertakes no obligation to release publicly any revisions, which
may be made to reflect events or circumstances after the date
hereof. DATASOURCE: ADVENTRX Pharmaceuticals, Inc. CONTACT: Andrea
Lynn of ADVENTRX Pharmaceuticals, Inc., +1-858-552-0866 Web site:
http://www.adventrx.com/ Company News On-Call:
http://www.prnewswire.com/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024